Skip to library content
Back to the shelf
Peptide library
In clinical trialsDigestive & weight

Enlicitide

Also called MK-0616

Evidence
Approved drug evidence
Class
Oral macrocyclic PCSK9 inhibitor peptide

Enlicitide belongs to the Oral macrocyclic PCSK9 inhibitor peptide class. This library groups it under digestive & weight. Its source category is In clinical trials.

Research libraryPeppy Care
Source snapshot
References4 linked sources

At a glance

Enlicitide research overview
Compound classOral macrocyclic PCSK9 inhibitor peptide
Body systemDigestive & weight
Use or research focusHypercholesterolemia
Regulatory statusInvestigational (Phase 3)
Source evidence ratingApproved drug evidence

How does Enlicitide work?

Blocks PCSK9 to lower LDL.

The source catalog maps this mechanism to Liver, Heart / Cardiovascular. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.

What does the evidence tell us?

This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.

Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.

Safety and considerations

A compound being studied in a clinical trial is not necessarily approved or effective. Trial participants follow a study protocol with eligibility criteria and monitoring. Results from one population or formulation may not apply to another.

This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.

Common questions

What is Enlicitide?

Enlicitide belongs to the Oral macrocyclic PCSK9 inhibitor peptide class. This library groups it under digestive & weight. Its source category is In clinical trials. Its recorded use or research focus is: Hypercholesterolemia.

Is Enlicitide FDA-approved?

The catalog records: Investigational (Phase 3). Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.

How strong is the research?

This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.

Where can I read the research?

The Citations tab contains 4 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.

More for digestive & weight

Factual catalog fields and citation links are adapted from Superpower’s Enlicitide guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.